强迫症中的谷氨酸能增强策略。
Glutamatergic augmentation strategies in obsessive-compulsive disorder.
作者信息
Sheshachala Karthik, Narayanaswamy Janardhanan C
机构信息
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
出版信息
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S58-S65. doi: 10.4103/psychiatry.IndianJPsychiatry_520_18.
Abstract
Proven treatment strategies for obsessive-compulsive disorder (OCD) include pharmacotherapy with serotonin reuptake inhibitors and cognitive behavior therapy (CBT). A significant proportion of patients (25%-30%) fail to respond to these treatment options, necessitating the need for additional treatment options to improve treatment outcomes and quality of life in patients with OCD. Augmentation strategies using various glutamatergic agents have been explored, with diverse outcomes. The aim of this review is to give an overview of the glutamatergic system in the brain with a focus on glutamatergic abnormalities in OCD and to review the existing evidence for various glutamatergic agents used for augmentation.
摘要
强迫症（OCD）经证实的治疗策略包括使用5-羟色胺再摄取抑制剂进行药物治疗以及认知行为疗法（CBT）。相当一部分患者（25%-30%）对这些治疗方案没有反应，因此需要额外的治疗方案来改善强迫症患者的治疗效果和生活质量。人们已经探索了使用各种谷氨酸能药物的增效策略，结果各不相同。这篇综述的目的是概述大脑中的谷氨酸能系统，重点关注强迫症中的谷氨酸能异常，并综述用于增效的各种谷氨酸能药物的现有证据。
相似文献
1
Glutamatergic augmentation strategies in obsessive-compulsive disorder.
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S58-S65. doi: 10.4103/psychiatry.IndianJPsychiatry_520_18.
2
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645.
3
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
JAMA Psychiatry. 2016 Aug 1;73(8):779-88. doi: 10.1001/jamapsychiatry.2016.1128.
4
Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
Int J Psychiatry Clin Pract. 2022 Nov;26(4):395-400. doi: 10.1080/13651501.2022.2054351. Epub 2022 Mar 24.
5
Obsessive compulsive disorder and the glutamatergic system.
Curr Opin Psychiatry. 2014 Jan;27(1):32-7. doi: 10.1097/YCO.0000000000000017.
6
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
JAMA. 2011 Sep 21;306(11):1224-32. doi: 10.1001/jama.2011.1344.
7
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Psychopharmacology (Berl). 2006 Jan;184(2):254-6. doi: 10.1007/s00213-005-0246-6. Epub 2005 Dec 22.
8
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
9
Mindfulness-based cognitive therapy as an augmentation treatment for obsessive-compulsive disorder.
Clin Psychol Psychother. 2017 Sep;24(5):1109-1120. doi: 10.1002/cpp.2076. Epub 2017 Feb 13.
10
Assessment and management of treatment-refractory obsessive-compulsive disorder in children.
J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):251-62. doi: 10.1016/j.jaac.2015.01.011. Epub 2015 Jan 30.
引用本文的文献
1
Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial.
BMC Psychiatry. 2025 Jun 2;25(1):561. doi: 10.1186/s12888-025-06856-7.
2
Psilocybin in pharmacotherapy of obsessive-compulsive disorder.
Pharmacol Rep. 2024 Oct;76(5):911-925. doi: 10.1007/s43440-024-00633-1. Epub 2024 Aug 1.
3
Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.
Cureus. 2023 Apr 19;15(4):e37833. doi: 10.7759/cureus.37833. eCollection 2023 Apr.
4
Epigenetic modifications and obsessive-compulsive disorder: what do we know?
Brain Struct Funct. 2023 Jun;228(5):1295-1305. doi: 10.1007/s00429-023-02649-4. Epub 2023 May 19.
5
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.
BMC Pharmacol Toxicol. 2021 Nov 4;22(1):69. doi: 10.1186/s40360-021-00534-6.
6
Brain areas involved with obsessive-compulsive disorder present different DNA methylation modulation.
BMC Genom Data. 2021 Oct 30;22(1):45. doi: 10.1186/s12863-021-00993-0.
7
Lower Ventromedial Prefrontal Cortex Glutamate Levels in Patients With Obsessive-Compulsive Disorder.
Front Psychiatry. 2021 Jun 8;12:668304. doi: 10.3389/fpsyt.2021.668304. eCollection 2021.
8
Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.
J Clin Psychiatry. 2020 Sep 8;81(5):19ac13182. doi: 10.4088/JCP.19ac13182.
9
Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.
Neuropsychiatr Dis Treat. 2020 Apr 17;16:1003-1013. doi: 10.2147/NDT.S211703. eCollection 2020.
10
An MRI Study of the Metabolic and Structural Abnormalities in Obsessive-Compulsive Disorder.
Front Hum Neurosci. 2019 Jun 26;13:186. doi: 10.3389/fnhum.2019.00186. eCollection 2019.
本文引用的文献
1
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
Pharmacopsychiatry. 2018 Nov;51(6):229-242. doi: 10.1055/s-0043-118665. Epub 2017 Sep 26.
2
Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis.
Mol Psychiatry. 2018 May;23(5):1181-1188. doi: 10.1038/mp.2017.154. Epub 2017 Aug 1.
3
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
J Clin Psychiatry. 2017 Jul;78(7):e766-e773. doi: 10.4088/JCP.16m11101.
4
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.
PLoS One. 2017 Mar 10;12(3):e0173660. doi: 10.1371/journal.pone.0173660. eCollection 2017.
5
Clinical practice guidelines for Obsessive-Compulsive Disorder.
Indian J Psychiatry. 2017 Jan;59(Suppl 1):S74-S90. doi: 10.4103/0019-5545.196976.
6
Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Iran J Psychiatry. 2016 Apr;11(2):104-14.
7
Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
JAMA Psychiatry. 2016 Aug 1;73(8):779-88. doi: 10.1001/jamapsychiatry.2016.1128.
8
Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
Psychiatry Clin Neurosci. 2016 Aug;70(8):332-41. doi: 10.1111/pcn.12394. Epub 2016 May 26.
9
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.
J Clin Psychiatry. 2016 Mar;77(3):408-9. doi: 10.4088/JCP.15l10138.
10
N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
J Clin Pharm Ther. 2016 Apr;41(2):214-9. doi: 10.1111/jcpt.12370. Epub 2016 Mar 2.
Zotero 插件